Results 61 to 70 of about 2,377 (150)

Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis [PDF]

, 2016
Data from multiple sclerosis (MS) and the MS rodent model, experimental autoimmune encephalomyelitis (EAE), highlighted an inflammation-dependent synaptopathy at the basis of the neurodegenerative damage causing irreversible disability in these disorders.
De Vito, F, Antonietta Gentile, Battistini, L, CENTONZE, DIEGO, Centonze, D, Francesca Gargano, Gentile, A, Borsellino, G, Roberta Fantozzi, Eleonora Piras, Diego Fresegna, Diego Centonze, PIRAS, ELEONORA, MUSELLA, ALESSANDRA, Bullitta, S, Musella, A, Giovanna Borsellino, GARGANO, FRANCESCA, Gargano, F, Alessandra Musella, Piras, E, Schubart, A, GENTILE, ANTONIETTA, FRESEGNA, DIEGO, Luca Battistini, Georgia Mandolesi, BULLITTA, SILVIA, Fantozzi, R, Fresegna, D, Silvia Bullitta, Mandolesi, G, Francesca De Vito, Anna Schubart   +32 more
core   +1 more source

Targeting progressive multiple sclerosis: Toward mechanism‐informed precision medicine

Journal of Internal Medicine, Volume 300, Issue 3, Page 238-257, September 2026.
Abstract Multiple sclerosis has undergone a therapeutic revolution over the past three decades. Randomized clinical trials and real‐world data demonstrate that modern disease‐modifying therapies substantially reduce relapse rates and acute inflammatory activity detected by magnetic resonance imaging (MRI).
Fredrik Piehl, Gonçalo Castelo‐Branco, Maja Jagodic, Tomas Olsson   +3 more
wiley   +1 more source

Spatiotemporal control of siponimod delivery for the regeneration of critical bone defects [PDF]

, 2021
Tissue engineering aims at regenerating damaged tissue by using synthetic or natural materials and has applications across the different tissue types, including bone.
Sartawi, Ziad
core   +1 more source

Bridging the Pregnancy Knowledge Gap: A Real‐World Analysis of Medication Use and Drug–Drug Interaction Risk in Crohn's Disease and Multiple Sclerosis

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT The exclusion of pregnant individuals from clinical trials has resulted in a significant medical knowledge gap for this population. Leveraging real‐world data (RWD) provides a critical window into the prevalence and use of medications during pregnancy.
Jacqueline Williams, Rucha Sane, Amita Joshi, Kit Wun Kathy Cheung, Bianca Vora   +4 more
wiley   +1 more source

First in vivo fluorine-19 magnetic resonance imaging of the multiple sclerosis drug siponimod [PDF]

, 2023
Theranostic imaging methods could greatly enhance our understanding of the distribution of CNS-acting drugs in individual patients. Fluorine-19 magnetic resonance imaging ((19)F MRI) offers the opportunity to localize and quantify fluorinated drugs non ...
Millward, J.M., Sherazi, F., Paul, F., Niendorf, T., Lippert, C., Prinz, C., Starke, L., Waiczies, H., Nazaré, M., Waiczies, S.   +9 more
core   +1 more source

Re-emergence of T lymphocyte-mediated synaptopathy in progressive multiple sclerosis

Frontiers in Immunology
BackgroundSecondary progressive multiple sclerosis (SPMS) is defined by the irreversible accumulation of disability following a relapsing-remitting MS (RRMS) course. Despite treatments advances, a reliable tool able to capture the transition from RRMS to
Krizia Sanna, Antonio Bruno, Antonio Bruno, Sara Balletta, Silvia Caioli, Monica Nencini, Diego Fresegna, Diego Fresegna, Livia Guadalupi, Livia Guadalupi, Ettore Dolcetti, Ettore Dolcetti, Federica Azzolini, Fabio Buttari, Fabio Buttari, Roberta Fantozzi, Angela Borrelli, Mario Stampanoni Bassi, Luana Gilio, Gianluca Lauritano, Gianluca Lauritano, Valentina Vanni, Francesca De Vito, Alice Tartacca, Fabrizio Mariani, Valentina Rovella, Alessandra Musella, Alessandra Musella, Diego Centonze, Diego Centonze, Georgia Mandolesi, Georgia Mandolesi   +31 more
doaj   +1 more source

Channel Dysfunction as the Basis for Comorbidities in Multiple Sclerosis and Depression

Archiv der Pharmazie, Volume 359, Issue 6, June 2026.
Ion channel remodelling induced by neuroinflammation in multiple sclerosis alters neuronal excitability and immune signalling, creating shared molecular pathways that link multiple sclerosis pathology to depression and reveal novel pharmacological targets.
Nicole Rychlik, Kay Jüngling, Sven G. Meuth, Thomas Budde, Marta Méndez‐Couz   +4 more
wiley   +1 more source

The neuro‐immune interface in multiple sclerosis: From pathogenesis to therapeutic opportunities

Brain‐X, Volume 4, Issue 2, June 2026.
This review analyzes the immunopathology of multiple sclerosis (MS), focusing on the interactions between innate and adaptive immunity, glial cells, and key molecular mechanisms such as MHC, chemokines, cytokines, and the complement system. It also explores current and emerging therapeutic strategies, providing a comprehensive view of disease ...
Ruohan Wang, Mengqi Li, Xinyao Chen, Manling Lang, Qifei Cong   +4 more
wiley   +1 more source

When Treatment Turns to Stone: Injection‐Site Calcinosis Associated With Interferon‐β in Multiple Sclerosis: A Case Report

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Injection‐site calcinosis is a rare complication of interferon‐β therapy in multiple sclerosis. We report a 52‐year‐old woman with stable bilateral gluteal calcifications after long‐term subcutaneous interferon‐β‐1b therapy. Findings were most consistent with probable dystrophic calcinosis cutis secondary to chronic repeated injection‐site ...
Anna Walter, Adam Bott, Marianne Kiechle, Margret Hund‐Georgiadis   +3 more
wiley   +1 more source

A label‐free impedance assay in endothelial cells differentiates the activation and desensitization properties of clinical S1P1 agonists

FEBS Open Bio, 2020
Sphingosine‐1 phosphate receptor‐1 (S1P1) activation maintains endothelial barrier integrity, whereas S1P1 desensitization induces peripheral blood lymphopenia.
Patrick Grailhe, Asma Boutarfa‐Madec, Philippe Beauverger, Philip Janiak, Ashfaq A. Parkar   +4 more
doaj   +1 more source